Monte Rosa Therapeutics EBIT

As of the most recent data (June 2026), GLUE shows a EBIT of $-180M. That compares with $13M in the prior-year period — down 1470.7% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GLUE's EBIT is now $-180M (was $13M) — a 1470.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Monte Rosa Therapeutics is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. Monte Rosa Therapeutics is at $-180M, which is lower that average. That is roughly 100.8% below the sector mean. Use the comparison chart on this page to see how GLUE stacks up against individual peers as well.

Tracking GLUE's ebit over time shows whether Monte Rosa Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-180M That compares with $13M in the prior-year period — down 1470.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Monte Rosa Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-180M) with ownership activity and broader fundamentals.